Best Practice & Research Clinical Haematology
Volume 21, Issue 2 , Pages 177-192 , June 2008

Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity

  • Laura Johnston, MD (Assistant Professor of Medicine)

      Affiliations

    • Corresponding Author InformationTel.: +1 650 723 0822; Fax: +1 650 725 8950.

References 

  1. Sullivan K. Graft versus host disease. In:  Blume K,  Forman S,  Appelbaum F editor. Thomas' hematopoietic cell transplantation. 3rd ed.. Malden, MA: Blackwell Publishing Ltd; 2004;p. 635–664
  2. Jacobsohn DA. Acute graft-versus-host disease in children. Bone Marrow Transplantation. 2007;41:215–221[review]
  3. Hurley CK, Wagner JE, Setterholm MI, et al. Advances in HLA: practical implications for selecting adult donors and cord blood units. Biology of Blood and Marrow Transplantation. 2006 Jan;12(1 Suppl. 1):28–33
  4. Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. The New England Journal of Medicine. 1985 Sep 26;313(13):765–771
  5. Hurley CK, Baxter Lowe LA, Logan B, et al. National marrow donor program HLA-matching guidelines for unrelated marrow transplants. Biology of Blood and Marrow Transplantation. 2003 Oct;9(10):610–615
  6. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110:4576–4583
  7. Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002 Sep 1;100(5):1611–1618
  8. Gluckman E, Rocha V, Arcese W, et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Experimental Hematology. 2004 Apr;32(4):397–407
  9. Balduzzi A, Gooley T, Anasetti C, et al. Unrelated donor marrow transplantation in children. Blood. 1995 Oct 15;86(8):3247–3256
  10. Eapen M, Horowitz MM, Klein JP, et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. Journal of Clinical Oncology. 2004 Dec 15;22(24):4872–4880
  11. Grewal SS, Barker JN, Davies SM, et al. Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?. Blood. 2003 Jun 1;101(11):4233–4244
  12. Weisdorf DJ, Anasetti C, Antin JH, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood. 2002 Mar 15;99(6):1971–1977
  13. Yakoub-Agha I, Mesnil F, Kuentz M, et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. Journal of Clinical Oncology. 2006 Dec 20;24(36):5695–5702
  14. Cao TM, Tsai S, Kelley L, et al. Comparable survival and transplant-related mortality following allogeneic hematopoietic cell transplantation from HLA allele-matched unrelated and HLA-identical sibling donors. ASH Annual Meeting Abstracts. Blood. 2006 Nov 16;108(11):3146
  15. Cutler C, Li S, Ho VT, et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood. 2007 Apr 1;109(7):3108–3114
  16. Moore J, Nivison-Smith I, Goh K, et al. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biology of Blood and Marrow Transplantation. 2007 May;13(5):601–607
  17. Pasquini MC, Wang Z, Schneider L. Report on state of the art in blood and marrow transplantation: part I – CIBMTR summary slides, 2007. Center for International Blood and Marrow Transplant Research Newsletter (CIBMTR Newsletter). 2007 Dec;13(2):5–8[serial online]
  18. Cutler C, Giri S, Jeyapalan S, et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. Journal of Clinical Oncology. 2001 Aug 15;19(16):3685–3691
  19. Horan JT, Liesveld JL, Fernandez ID, et al. Survival after HLA-identical allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: meta-analysis of randomized controlled trials. Bone Marrow Transplantation. 2003 Aug;32(3):293–298
  20. Schmitz N, Eapen M, Horowitz MM, et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood. 2006 Dec 15;108(13):4288–4290
  21. Eapen M, Logan B, Confer DL, et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biology of Blood and Marrow Transplantation. 2007 Dec;13(12):1461–1468
  22. Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood. 2005 Feb 1;105(3):1343–1347
  23. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. The New England Journal of Medicine. 2004 Nov 25;351(22):2276–2285
  24. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. The New England Journal of Medicine. 2004 Nov 25;351(22):2265–2275
  25. Takahashi S, Iseki T, Ooi J, et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood. 2004 Dec 1;104(12):3813–3820
  26. Hwang WY, Samuel M, Tan D, et al. A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in adult and pediatric patients. Biology of Blood and Marrow Transplantation. 2007 Apr;13(4):444–453
  27. Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. The Lancet. 2007 Jun 9;369(9577):1947–1954
  28. Brunstein CG, Baker KS, Wagner JE. Umbilical cord blood transplantation for myeloid malignancies. Current Opinion in Hematology. 2007 Mar;14(2):162–169
  29. MacMillan ML, Brunstein C, DeFor TE, et al. Single versus double umbilical cord blood transplantation (UCBT): higher risk of acute graft-versus-host disease (GVHD) but lower transplant related mortality (TRM) in recipients of double UCBT. ASH Annual Meeting Abstracts. Blood. 2006 Nov 16;108(11):435
  30. Majhail NS, Brunstein CG, Wagner JE. Double umbilical cord blood transplantation. Current Opinion in Immunology. 2006 Oct;18(5):571–575
  31. Verneris MR, Brunstein C, DeFor TE, et al. Risk of relapse (REL) after umbilical cord blood transplantation (UCBT) in patients with acute leukemia: marked reduction in recipients of two units. ASH Annual Meeting Abstracts. Blood. 2005 Nov 16;106(11):305
  32. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. The New England Journal of Medicine. 1998 Nov 26;339(22):1565–1577
  33. Barker JN, Scaradavou A, Stevens CE, et al. Analysis of 608 umbilical cord blood (UCB) transplants: HLA-match is a critical determinant of transplant-related mortality (TRM) in the post-engraftment period even in the absence of acute graft-vs-host disease (aGVHD). ASH Annual Meeting Abstracts. 2005 Nov 16;106(11):303
  34. Wagner J, Champlin R, Petz LD. Fifth annual international umbilical cord blood transplantation symposium, Los Angeles, California, May 11–12, 2007. Biology of Blood and Marrow Transplantation. 2007 Nov;13(11):1380–1392
  35. Koh LP, Rizzieri DA, Chao NJ. Allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors. Biology of Blood and Marrow Transplantation. 2007 Nov;13(11):1249–1267
  36. Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biology of Blood and Marrow Transplantation. 1999;5(6):347–356
  37. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003 Jul 15;102(2):756–762
  38. Couriel DR, Saliba RM, Giralt S, et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biology of Blood and Marrow Transplantation. 2004 Mar;10(3):178–185
  39. Alyea EP, Kim HT, Ho V, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood. 2005 Feb 15;105(4):1810–1814
  40. Rodriguez R, Nademanee A, Ruel N, et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biology of Blood and Marrow Transplantation. 2006 Dec;12(12):1326–1334
  41. Van Besien K, Carreras J, Zhang M-J, et al. Reduced Intensity vs Myeloablative Conditioning for HLA Matched Sibling Transplantation in Follicular Lymphoma. Blood. 2005 Nov 16;106(11):656a
  42. Mielcarek M, Burroughs L, Leisenring W, et al. Prognostic relevance of ‘early-onset’ graft-versus-host disease following non-myeloablative haematopoietic cell transplantation. British Journal of Haematology. 2005 May;129(3):381–391
  43. Mielcarek M, Storer BE, Sandmaier BM, et al. Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors. Biology of Blood and Marrow Transplantation. 2007;13:1499–1507
  44. Barker JN, Weisdorf DJ, DeFor TE, et al. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood. 2003 Sep 1;102(5):1915–1919
  45. Ballen KK, Spitzer TR, Yeap BY, et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biology of Blood and Marrow Transplantation. 2007 Jan;13(1):82–89
  46. Majhail NS, Weisdorf DJ, Wagner JE, et al. Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. Blood. 2006 May 1;107(9):3804–3807
  47. Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood. 2004 Dec 15;104(13):3865–3871
  48. Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. Journal of Clinical Oncology. 2005 Dec 20;23(36):9387–9393
  49. van Besien K, Artz A, Smith S, et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. Journal of Clinical Oncology. 2005 Aug 20;23(24):5728–5738
  50. Perez-Simon JA, Kottaridis PD, Martino R, et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood. 2002 Nov 1;100(9):3121–3127
  51. Ho AY, Pagliuca A, Kenyon M, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood. 2004 Sep 15;104(6):1616–1623
  52. Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001 Nov 15;98(10):2942–2947
  53. Finke J, Schmoor C, Lang H, et al. Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin. Journal of Clinical Oncology. 2003 Feb 1;21(3):506–513
  54. Lowsky R, Takahashi T, Liu YP, et al. Protective conditioning for acute graft-versus-host disease. The New England Journal of Medicine. 2005 Sep 29;353(13):1321–1331

PII: S1521-6926(08)00007-8

doi: 10.1016/j.beha.2008.02.006

Best Practice & Research Clinical Haematology
Volume 21, Issue 2 , Pages 177-192 , June 2008

Article Tools

* Image Usage & Resolution